GlaxoSmithKline PLC (GSK)
Price/Share*: |
$44.75 |
Annualized Dividend: |
$2.25 |
Div. Yield: |
5.04% |
52-Week High: |
$46.50 |
% Off 52-Week High: |
-3.76% |
52-Week Low: |
$36.39 |
Recent/Upcoming Dividend Payouts for GSK
| Amount ¹ | Ex-Dividend Date | Record Date | Pay Date | Declare Date | Qualified? [?] | Type |
|---|---|---|---|---|---|---|
| $0.66339 | 2/15/2012 | 2/17/2012 | 4/12/2012 | N/A | Unknown | Regular |
| $0.15795 | 2/15/2012 | 2/17/2012 | 4/12/2012 | N/A | Unknown | Extra |
| $0.54298 | 11/2/2011 | 11/4/2011 | 1/5/2012 | N/A | Unknown | Regular |
| $0.521088 | 8/3/2011 | 8/5/2011 | 10/6/2011 | N/A | Unknown | Regular |
¹ Because this stock is foreign-based, please be advised payouts may be subject to foreign taxes.
View Historical Dividend Data for GSK »
Add GSK to My Watchlist »

DARS™ Stock Ratings for GSK
If you were a Dividend.com Premium member, you would be seeing detailed DARS™ Dividend Stock Ratings information for GlaxoSmithKline PLC (GSK) in this space, including whether we think your should Buy, Hold, or Sell this stock.
Sign up for Dividend.com Premium today to gain access to ratings on nearly 1,600 dividend-paying stocks, exclusive members-only articles, historical dividend information, and more!
Subscribe to Dividend.com Premium Today! »
Recent Dividend.com Articles for GSK
- Feb 4, 2012Best Large Cap Dividend Stock Prospects List - Feb.4 Edition
- Feb 1, 2012Best Large Cap Dividend Stock Prospects List - Year-To-Date Performance
- Jan 28, 2012Best Large Cap Dividend Stock Prospects List - Jan.28 Edition
- Jan 21, 2012Best Large Cap Dividend Stock Prospects List - Jan.21 Edition
- Jan 14, 2012Best Large Cap Dividend Stock Prospects List - Jan.14 Edition
- Jan 9, 2012Dividend Highlights and Lowlights for Jan. 9
- Jan 7, 2012Best Large Cap Dividend Stock Prospects List - Jan.7 Edition
- Jan 3, 2012Best Large Cap Dividend Stock Prospects List - Year-To-Date Performance
- Jan 2, 2012Best Large Cap Dividend Stock Prospects List - Dec.31 Edition
- Dec 24, 2011Best Large Cap Dividend Stock Prospects List - Dec.24 Edition
GlaxoSmithKline PLC (GSK) Company Profile
Glaxo-Smith Kline- (GSK)-engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical and consumer health-related products. The company's Consumer Healthcare segment offers over-the-counter medicines, oral care, and nutritional healthcare products. Its products comprise Lucozade energy and sports drinks; Aquafresh and Sensodyne toothpastes and mouthwashes; Aquafresh and Dr Best toothbrushes; Panadol, a paracetamol/acetaminophen analgesic; Horlicks, a milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in the United States, Europe, Japan, the Asia Pacific, the Middle East, Latin America, Africa, and Canada. It has agreements with Anacor Pharmaceuticals, Inc.; Oncomed Pharmaceuticals, Inc.; Santaris Pharma A/S; and Targacept, Inc. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.
* Stock price reflects previous day's closing price. All stock quotes on this website should be considered as having a 24-hour delay.
** Under no circumstances does the information on this website represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the "publisher's exclusion" from the definition of "investment adviser" as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.
*** All dividend payout and date information on this website is for information purposes only. We do not guarantee the accuracy of any dividend dates or payout amounts. Always check with your broker first before purchasing any security.

FREE Dividend Stock Newsletter
Get the Dividend.com email newsletter to receive:
- A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
- Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
- Tons of great market analysis and recommendations





RSS Feeds